Clinical Trial Update: Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating octreotide with or without prednisone for metastatic or recurrent thymoma/thymic carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma
• Thymoma

Drugs mentioned

• OCTREOTIDE (OCTREOTIDE ACETATE)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Thymoma and Thymic Carcinoma | Phase 2 | Status: COMPLETED